UNSPSC 51111638: Exatecan

This classification denotes a camptothecin analogue with the molecular formula C24H22FN3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OC71PP0F89, chemically known as 10h,13h-benzo(de)pyrano(3,4:6,7)indolizino(1,2-b)quinoline-10,13-dione, 1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-, (1s-trans)- but generally known as exatecan, which bears US NIH Compound Identifier 151115. The term EXATECAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, List 43).

Most nations schedule exatecan under HS 29399900 and SITC 54149. As of Q4 2014, EXATECAN remains the US FDA Preferred Term for this commodity. Exatecan bears US NLM identifiers UMLS ID C0965941 and NCI Concept Code C66720. SMILES: CCC1(C2=C(COC1=O)C(=O)N3CC4=C5C(CCC6=C5C(=CC(=C6C)F)N=C4C3=C2)N)O.

UNSPSC 51111638 Exatecan, a Commodity code, covers pharmaceutical products and services sourced by state health agencies to support prescription benefit programs and direct-to-manufacturer procurement arrangements. The single recent state-local opportunity under this code stems from a Texas Health and Human Services Commission Request for Information issued on April 3, 2026, exploring vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program designed to establish direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers outside traditional pharmacy benefit manager, group purchasing organization, and wholesaler channels. The scope targets vendors with experience in direct contracting for self-insured employers and health plans in both private and government sectors, flexibility to negotiate contracts based on negotiated net pricing models without rebates, and capability to implement value-based or outcomes-based agreements. The RFI is exploratory in nature and does not represent a formal competitive solicitation; it functions as market intelligence gathering before issuance of a formal RFP with established financial and temporal parameters.

Activity under this code appears concentrated in state health agencies conducting direct pharmacy benefit procurement. The Texas Health and Human Services Commission represents the only recent issuing body identified in the available record for this commodity. Geographic spread is limited to Texas based on current opportunities. The RFI did not specify set-aside designations, award values, budget ranges, or incumbent contractor information, as the state was in a preliminary fact-finding phase regarding available solutions and vendor capabilities rather than committing to specific contract amounts or durations.